Bioavailability of fondaparinux to critically ill patients

Journal of Critical Care

Volumn 26, Issue 4, 2011, Pages 342-346

  Cumbo Nacheli, Gustavo ^a   Samavati, Lobelia ^b   Guzman, Jorge A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioavailability; Critically ill; Fondaparinux; Intensive care unit; Vasopressors; Venous thromboembolism

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 10A ANTIBODY; DOPAMINE; FONDAPARINUX; HYPERTENSIVE FACTOR; NORADRENALIN; PHENYLEPHRINE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASOPRESSIN;

ADULT; APACHE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; MULTICENTER STUDY; PATIENT MONITORING; PRESSOR RESPONSE; PROSPECTIVE STUDY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; CRITICAL ILLNESS; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; PROSPECTIVE STUDIES; THROMBOEMBOLISM;

EID: 79960698995     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2010.08.004     Document Type: Article

References (22)

1. Geerts W., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(Suppl):338S-400S.
2. Schonhofer B., Kohler D. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiration 1998, 65:173-177.
3. Geerts W.H., Bergqvist D., Pineo G.F., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl):381S-453S.
4. Cohen A.T., Davidson B.L., Gallus A.S., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ 2006, 332(7537):325-329.
5. Dixon B. The role of microvascular thrombosis in sepsis. Anaesth Intensive Care 2004, 32(5):619-629.
6. Cook D., Douketis J., Meade M., et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care 2008, 12(2):R32.
7. Crowther M., Lim W. Measuring the anticoagulant effect of low molecular weight heparins in the critically ill. Crit Care 2006, 10(4):150.
8. Dörffler-Melly J., de Jonge E., de Pont A.C., et al. Bioavailability of subcutaneous low molecular-weight heparin to patients on vasopressors. Lancet 2002, 359:849-850.
9. Agnelli G., Bergqvist D., Cohen A.T., et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005, 92(10):1212-1220.
10. Bauer K.A., Eriksson B.I., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001, 345(18):1305-1310.
11. Wester J.P., Leyte A., Oudemans-van Straaten H.M., et al. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill. Neth J Med 2007 Mar, 65(3):101-108.
12. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295(13):1519-1530.
13. Fox K.A., Bassand J.P., Mehta S.R., et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med 2007, 147:304-310.
14. Krishnan V., Murray P. Pharmacologic issues in the critically ill. Clin Chest Med 2003, 24:671-688.
15. Robinson S., Zincuk A., Strøm T., et al. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit Care 2010, 14(2):R41.
16. Malinoski D., Jafari F., Ewing T., et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J Trauma 2010, 68(4):874-880.
17. Priglinger U., Delle Karth G., Geppert A., et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill?. Crit Care Med 2003, 31:1405-1409.
18. Cook D., Crowther M., Meade M., et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005, 33:1565-1571.
19. Holmes C.L., Walley K.R. Bad medicine: low-dose dopamine in the ICU. Chest 2003, 123:1266-1275.
20. Rommers M.K., Van der Lely N., Egberts T.C., et al. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 2006, 10(3):R93.
21. Mayr A.J., Dünser M., Jochberger S., et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res 2002, 105:201-204.
22. Wood G.C., Swanson J.M., Boucher B.A. Pharmacokinetic changes in critical illness. Crit Care Clin 2006, 22(2):255-271.